retatrutide glp-3rt (Retatrutide)12MG Retatrutide | Triple Agonist Research

Adems, me informaron detalladamente sobre las instrucciones de uso, cmo funciona el medicamento y sus posibles efectos secundarios

29 In a systematic review and meta-analysis pooling these and other studies, Amaral et al found that the risk of glaucoma development was lower in patients taking GLP-1 RAs (HR = .71) compared with controls

This Phase 3 trial, completed in December of the previous year, enrolled participants with obesity and knee osteoarthritis

By submitting this form you agree to be contacted via phone/text/email.

According to FDA prescribing information, these effects vary by product and dose: For Ozempic (diabetes treatment): Nausea (15-20% of patients) Diarrhea (8-9% of patients) Vomiting (5-9% of patients) Constipation (3-7% of patients) Abdominal pain (5-6% of patients) For Wegovy (weight management), gastrointestinal effects are more common at the higher therapeutic dose: Nausea (up to 44% of patients) Diarrhea (up to 30% of patients) Vomiting (up to 24% of patients) Constipation (up to 24% of patients) Abdominal pain (up to 20% of patients) These effects are generally mild to moderate and tend to diminish with continued use